120 filings
8-K
RLMD
Relmada Therapeutics Inc
19 Mar 24
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
4:10pm
8-K
RLMD
Relmada Therapeutics Inc
11 Jan 24
Departure of Directors or Certain Officers
4:30pm
8-K
RLMD
Relmada Therapeutics Inc
4 Jan 24
Relmada Therapeutics Provides Corporate Update
8:11am
8-K
RLMD
Relmada Therapeutics Inc
3 Jan 24
Departure of Directors or Certain Officers
5:00pm
8-K
RLMD
Relmada Therapeutics Inc
8 Nov 23
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:01pm
8-K
avosios
11 Oct 23
Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023
9:00am
8-K
g0p0 z4z153alrsp0mw
10 Oct 23
Targeting Major Advances in the Treatment of CNS Disorders October 10 th , 2023
5:18pm
8-K
ftixmc
4 Oct 23
Targeting Major Advances in the Treatment of CNS Disorders October 4 th , 2023
8:53am
8-K
jb7 c0rj6hfuf
20 Sep 23
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder
4:47pm
8-K
6lpulowoyxj1wjg qhvu
6 Sep 23
Departure of Directors or Certain Officers
9:23am
8-K
gikrcl9xqa 2l4
10 Aug 23
Targeting Major Advances in the Treatment of CNS Disorders August 10 th , 2023
4:54pm
8-K
i1u st3sywi
8 Aug 23
Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:29pm
8-K
nuoam
25 May 23
Departure of Directors or Certain Officers
4:28pm
8-K
kwsrsv60sl80 97
15 May 23
Targeting Major Advances in the Treatment of CNS Disorders May 15 th , 2023
5:29pm
8-K
mnigkjya3d 4hhz02
11 May 23
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:48pm
8-K
yzsbr96smb o8
19 Apr 23
Targeting Major Advances in the Treatment of CNS Disorders April 19th, 2023
9:25am
8-K
7ksfgfrjr2724sz
23 Mar 23
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
4:05pm
8-K
oubtg7
13 Mar 23
Regulation FD Disclosure
8:30am
8-K
2o76fm 8o
13 Jan 23
Entry into a Material Definitive Agreement
5:34pm
8-K
5kwk8wh wa
9 Jan 23
Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O’Gorman MD as Chief Medical Officer
8:38am